Chelsie Derman

A study found no differences in depressive symptom reduction when nonresponders continued therapy, switched therapists, or changed both therapist and treatment approach.

Alixorexton receives FDA Breakthrough Therapy Designation, promising significant advancements in treating narcolepsy type 1.

Q4 2025 brought key FDA approvals and phase 3 advances in HAE, peanut allergy, multi-allergen immunotherapy, and allergic fungal rhinosinusitis.

A study identified early symptom improvement and greater baseline depression severity as predictors of sustained antidepressant response to adjunctive cariprazine in MDD.

December 2025 psychiatry updates: Teva files TEV-‘749 for schizophrenia, lumateperone boosts MDD outcomes, AGA tied to mental health, and a look back at 2025 advances.

December highlights: FDA approval of berotralstat for pediatric HAE, phase 3 RAPIDe-3 results, and allergy field spotlights in our This Year in Medicine series.

From FDA decisions to late-phase trial readouts and updated practice guidelines, 2025 delivered clinically actionable insights across sleep conditions.

In 2025, psychiatry saw major FDA approvals, novel treatments, and pivotal clinical updates that are transforming care for depression, ADHD, schizophrenia, and anxiety.

Significant advancements in allergy treatments emerge in 2025, including 4 FDA approved treatments for hereditary angioedema.

A review found increased anxiety, depression, social anxiety, and perceived stress among individuals with androgenetic alopecia compared with those without the condition.

A study found that higher PM2.5 exposure during the first year after NICU discharge increased asthma risk in children with bronchopulmonary dysplasia by age 5.

Innovative therapies and devices are transforming food allergy management, enhancing safety and quality of life for patients and families.

A review shows that real-world persistence with asthma biologics depends not only on efficacy, but also on patient perceptions and mental health.

Study finds comparable IgE reductions with heated milk and conventional desensitization, but heated milk linked to higher anaphylaxis risk in children with cow’s milk allergy.

In a new study, children exposed to gestational diabetes showed lower FEV1 and increased odds of current asthma at ages 8–9 years.

Registry data show worse asthma control, more exacerbations, and higher healthcare utilization in patients with severe asthma and a comorbid sleep disorder.

DBV Technologies announced that the phase 3 VITESSE trial on VIASKIN® Peanut patch for peanut-allergic children met its primary endpoint.

FibroGen’s oral HIF-PH inhibitor showed improved transfusion independence in high–high-transfusion-burden MDS patients in a post hoc phase 3 MATTERHORN analysis.

Berotralstat (ORLADEYO) oral pellets become the first FDA-approved therapy specifically designed to prevent HAE attacks in children aged 2 – 11 years.

A 20-year population study found unilateral adrenalectomy raises long-term risks of CKD and gout in primary aldosteronism.

A review in Wichita, Kansas, shows asthma-related emergency visits spike during storms, underscoring the importance of weather-based asthma action plans for at-risk patients.

Study shows house dust mite SLIT therapy is safe in children with allergic asthma, though COVID-19–related drops in exacerbations impacted the primary endpoint.

Teva submitted an NDA on olanzapine extended-release injectable suspension (TEV-‘749) for adult schizophrenia to the FDA.

Following its 2025 FDA approval, lumateperone 42 mg demonstrated meaningful reductions in MADRS and CGI-S scores in adults with major depressive disorder.

Oral bradykinin B2 receptor antagonist resolved HAE attacks in under 90 minutes, with most patients needing only a single dose and no rescue medication.

A survey found many obstetric physicians rarely refer pregnant patients for allergy or immunology care, citing knowledge gaps and long wait times.

This month in review highlights November’s biggest psychiatry stories, including FDA moves, phase 4 findings, and new data on digital mental health tools.

This month in review spotlights 5 top allergy headlines published in November, including late-breaking data at ACAAI 2025.

The oral C5aR inhibitor produced durable responses across multiple doses in an 8-week trial, prompting InflaRx to move forward with phase 2b development.

Board-certified allergist shares how clinicians can better recognize and prevent atopic dermatitis in patients with skin of color, addressing pigmentation.